A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 07 Mar 2016 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2016 Status changed from recruiting to active, no longer recruiting,as reported by ClinicalTrials.gov.